Climb Bio To Present At The 24Th Annual Needham Virtual Healthcare Conference

2025-03-27 07:16:37

(MENAFN- GlobeNewsWire - Nasdaq) WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24^th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.

24 ^th Annual Needham Virtual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: April 10, 2025
Time: 8:45 a.m. ET
Webcast: Click here

About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com .

Investors
Chris Brinzey
ICR Healthcare
...
339-970-2843

Media
Jon Yu
ICR Healthcare
...
475-395-5375

MENAFN27032025004107003653ID1109363614

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.